tirzepatide grapevine Dual Agonist (GLP-1/GIP) The Semaglutide and Tirzepatide Difference

Teratogenicity studies show no increased incidence of congenital abnormalities in offspring of treated animals

References 1 AfshariA

Semaglutidethe active ingredient in Wegovyproduces measurable weight loss within the first three months for most patients, with clinical trials showing an average of 5 to 10 percent body weight reduction by week 12

This means it targets not only GLP-1 but also GIP, another hormone that impacts insulin sensitivity and appetite control

Galactose lectin-3 (Gal-3) protein is closely associated with inflammation and liver fibrosis

Oral Microbiome What it is: Your mouth is a window into your total health